GILD logo

GILD
Gilead Sciences, Inc.

77,676
Mkt Cap
$148.64B
Volume
10.03M
52W High
$124.61
52W Low
$86.08
PE Ratio
23.83
GILD Fundamentals
Price
$118.89
Prev Close
$118.44
Open
$116.06
50D MA
$115.69
Beta
0.36
Avg. Volume
7.21M
EPS (Annual)
$0.3825
P/B
7.56
Rev/Employee
$1.63M
Loading...
Loading...
News
all
press releases
GILD Q3 Earnings and Sales Beat Estimates, HIV and Livdelzi Sales Grow
Gilead posts upbeat Q3 results on strong HIV and Livdelzi sales, but shares slip despite earnings and revenue beats.
Zacks·2d ago
News Placeholder
More News
News Placeholder
Gilead Sciences Wins Prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product With Yeztugo (Lenacapavir)
Gilead Sciences, Inc. (Nasdaq: GILD) today announced it has been awarded the prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product for Yeztugo (lenacapavir), the companys...
Business Wire·2d ago
News Placeholder
Gilead (GILD) Reports Q3 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Gilead (GILD) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks·3d ago
News Placeholder
Gilead Sciences (GILD) Q3 Earnings and Revenues Top Estimates
Gilead (GILD) delivered earnings and revenue surprises of +14.88% and +4.16%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3d ago
News Placeholder
Gilead Sciences Announces Third Quarter 2025 Financial Results
Gilead Sciences, Inc. (Nasdaq: GILD) announced today its third quarter 2025 results of operations. We continue to deliver on Gilead's robust portfolio with a strong start for Yeztugo, rapidly growing...
Business Wire·3d ago
News Placeholder
Should You Buy, Hold, or Sell GILD Stock Ahead of Q3 Earnings?
Gilead Sciences gears up for Q3 results with strong HIV gains and new FDA approvals, amid challenges in its Cell Therapy business.
Zacks·4d ago
News Placeholder
Earnings Preview: AC Immune (ACIU) Q3 Earnings Expected to Decline
AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·5d ago
News Placeholder
What's in Store for These 5 Pharma Bigwigs This Earnings Season?
As earnings season accelerates, pharma heavyweights LLY, MRK, ABBV, BMY and GILD prepare to reveal their Q3 results amid a strong sector start.
Zacks·6d ago
News Placeholder
Key Events This Extremely Busy Week: Central Banks, Earnings Galore, And Trump-Xi Summit
Key Events This Extremely Busy Week: Central Banks, Earnings Galore, And Trump-Xi Summit As noted earlier, investors face a monumentally important and extremely busy week ahead that includes rates...
Zero Hedge·6d ago
News Placeholder
Curious about Gilead (GILD) Q3 Performance? Explore Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Gilead (GILD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2025.
Zacks·6d ago

Latest GILD News

View

Advertisement|Remove ads.

Advertisement|Remove ads.